14 completed. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 2 | Completed 2 |
Follow Bone Cysts: new trials by email Literature Review of Bone Cysts trials Research Report on Bone Cysts
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome PTX-022, Vehicle comparator - BCCs in Gorlin Syndrome Patients | Phase 2 | Completed | Palvella Therapeutics, Inc. | 73 | 2021-05-06 | 2024-08-29 |
| Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor ASN-002 - Basal Cell Carcinoma, Basal Cell Nevus Syndrome | Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 21 | 2020-07-16 | 2024-04-10 |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Patidegib, Vehicle gel - Basal Cell Carcinomas | Phase 2 | Completed | PellePharm, Inc. | 36 | 2016-11-11 | 2019-01-08 |
| Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Patidegib, Vehicle gel - Basal Cell Nevus Syndrome | Phase 2 | Completed | PellePharm, Inc. | 17 | 2016-06-06 | 2020-07-23 |
| A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors vismodegib - Keratocystic Odontogenic Tumor | Phase 2 | Completed | NYU College of Dentistry | 2 | 2015-10-27 | 2021-02-18 |
| A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma ASN-002, 5-FU - Basal Cell Nevus Syndrome, Skin Neoplasm | Phase 1 / Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 16 | 2015-09-01 | 2018-06-06 |
| Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Denosumab (Xgeva) - Bone Cyst Aneurysmal, Pathological Fracture | Phase 1 / Phase 2 | Completed | Peking University People's Hospital | 6 | 2014-01-01 | 2018-01-30 |
| Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Carboplatin, Cognitive Assessment, Cyclophosphamide - Desmoplastic/Nodular Medulloblastoma, Medulloblastoma | Phase 2 | Completed | Children's Oncology Group | 26 | 2013-12-24 | 2023-01-09 |
| Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas Vismodegib, Aminolevulinic acid %20 topical solution - Basal Cell Nevus Syndrome, Gorlin's Syndrome | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 24 | 2012-04-01 | 2020-11-02 |
| Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) LDE225, Placebo - Basal Cell Carcinoma, Gorlin Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 10 | 2011-04-01 | 2015-10-19 |
| To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) GDC-0449 - Basal Cell Nevus Syndrome, Gorlin Syndrome | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 41 | 2009-08-01 | 2021-01-11 |
| A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients Vehicle, LDE225 0.25%, LDE225 0.75% - Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients | Phase 2 | Completed | Novartis Pharmaceuticals | 18 | 2009-07-01 | 2015-11-03 |
| Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back tazarotene, placebo - Skin Carcinoma | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 34 | 2004-07-01 | 2016-02-11 |
| Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face tazarotene - Neoplastic Syndrome | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 36 | 2004-07-01 | 2020-10-29 |
Basal Cell Nevus Syndrome (12) · Carcinoma, Basal Cell (9) · Neoplasms (2) · Bone Cysts, Aneurysmal (1) · Fractures, Spontaneous (1) · Medulloblastoma (1) · Odontogenic Cysts (1) · Recurrence (1) · Skin Neoplasms (1)
Cysts (14) · Musculoskeletal Diseases (14) · Bone Diseases (13) · Jaw Cysts (13) · Jaw Diseases (13) · Stomatognathic Diseases (13) · Abnormalities, Multiple (12) · Bone Diseases, Developmental (12) · Carcinoma (12) · Congenital Abnormalities (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Neoplasms (12) · Neoplasms by Histologic Type (12)
HhAntag691 (3) · Drug Evaluation (2) · IPI-926 (2) · gusacitinib (2) · tazarotene (2) · Aminolevulinic Acid (1) · Carboplatin (1) · Cyclophosphamide (1) · Denosumab (1) · Etoposide (1) · Fluorouracil (1) · Mental Status and Dementia Tests (1) · Methotrexate (1) · Surgical Procedures, Operative (1) · Vincristine (1)
UCSF Benioff Children's Hospital Oakland (4) · Ascend Biopharmaceuticals Ltd (2) · Novartis Pharmaceuticals (2) · PellePharm, Inc. (2) · Children's Oncology Group (1) · NYU College of Dentistry (1) · Palvella Therapeutics, Inc. (1) · Peking University People's Hospital (1)
United States (8) · Australia (3) · Austria (2) · Canada (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Puerto Rico (1) · Switzerland (1)
Ervin Epstein, MD (5) · David R. Bickers, MD (2) · Gregory Siller (2) · Brian L Schmidt, DDS, MD, PhD (1) · Clement Leong, Ph.D (1) · David Bickers, MD (1) · John Lear, MD (1) · Joyce Teng, MD (1) · Lucie E Lafay-Cousin (1) · Lynda Spelman (1) · Rodney Sinclair (1)
PMID 22670904, PMID 24441673, PMID 24623282, PMID 27838224
R01CA109584 (2), 2015 (1), U10CA098543 (1), U10CA180886 (1), U19CA081888 (1)